Pharma MNCs Expanding in China 2016-2016.doc

Pharma MNCs Expanding in China: Milestones 2005-2009 Author：China Pharmaceutical Review?? Source：Transmedia Healthcare Information Solutions On 30th October 2004, Roche’s fifth global RD center started operation in ShanghaiPudong Zhangjiang Hi-tech Park, making itself the first wholly owned and operated RD?center set up in China by a pharma MNC. The establishment of Roche’s Shanghai RD Center is regarded by industry analysts asa turning point in the China strategy of pharma MNCs. In the wake of Roche, and since?2005, pharma MNCs have not only accelerated their pace to establish research input in China,?but also geared up investment in building new facilities or expanding current production sites.?China Pharmaceutical Review?summarizes the main expansion activities of eight leadingpharma MNCs in China. ＊AstraZeneca August 2005 AstraZeneca China disclosed in Shanghai that it will up investment by US$ 35 million?and recruit some 500 new employees to expand the production capacity of its Wuxi facility.?The manufacturing plant located in Wuxi, Jiangsu province, is AstraZeneca’s biggest?production base in Asia with an investment of US$170 million. April 2006 AstraZeneca celebrated the 5th anniversary of its Wuxi Site, and unveiled a new US$3.8?million packing line which will increase the annual capacity by 40 million packages. May 2006 AstraZeneca announced in Beijing its intention to invest US$100 million in RD in China?over the next three years, focusing on the benefit and value of innovative medicines for?Chinese patients. The prime focus of this program will be the establishment of the?AstraZeneca Innovation Centre China. January 2007 AstraZeneca’s China sourcing centre was founded in Shanghai as part of the company’seffort to strengthen global sourcing of active pharmaceutical ingredients. March 2007 AstraZeneca announced Shanghai’s Zhangjiang Hi-Tech Park as the initial base for its?new Innovation Centre China (ICC). September?2007 AstraZeneca